EP0784974A1 - Solid dispersion or solid dispersion preparation of xanthine derivatives - Google Patents
Solid dispersion or solid dispersion preparation of xanthine derivatives Download PDFInfo
- Publication number
- EP0784974A1 EP0784974A1 EP96916342A EP96916342A EP0784974A1 EP 0784974 A1 EP0784974 A1 EP 0784974A1 EP 96916342 A EP96916342 A EP 96916342A EP 96916342 A EP96916342 A EP 96916342A EP 0784974 A1 EP0784974 A1 EP 0784974A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- solid dispersion
- compound
- polymer
- examples
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC1C(C(C)C2)(C2C2)C12c1nc(N(*)C(N(*)C2=O)=O)c2[n]1 Chemical compound CC1C(C(C)C2)(C2C2)C12c1nc(N(*)C(N(*)C2=O)=O)c2[n]1 0.000 description 1
- ZHFHGJLOPHUQQX-UHFFFAOYSA-N CCC(C(C1C)O)C([I]=C(C2I)C(CC3C4)(C56)C35C4C6O)=C2C1O Chemical compound CCC(C(C1C)O)C([I]=C(C2I)C(CC3C4)(C56)C35C4C6O)=C2C1O ZHFHGJLOPHUQQX-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Definitions
- the present invention relates to a solid dispersion and a solid dispersion dosage form of a xanthine derivative or a pharmacologically allowable salt thereof which exhibits an antagonistic activity relative to the adenosine A1 receptor, and which has a diuretic activity, a kidney-protecting activity, a bronchodilating activity, a cerebral function-improving activity, an anti-dementia activity, or the like.
- drugs which are slightly soluble in water and have high crystallinity have low bioavailability since they have low solubility and low disolution rate in the gastrointestinal tract. Hitherto, in order to improve their absorbability, several methods for finely grinding drug crystals or for transforming them into amorphous substances have been examined.
- the present invention relates to a solid dispersion comprising a xanthine derivative or a pharmacologically allowable salt thereof and a polymer, the xanthine derivative [hereinafter referred to as compound (I)] being represented by the following formula (I).
- compound (I) being represented by the following formula (I).
- R 1 and R 2 are the same or different, and represent substituted or unsubstituted lower alkyl groups, and Q represents a hydrogen atom or a hydroxyl group.
- the present invention relates to a solid dispersion dosage form comprising a xanthine derivative of a compound (I) or a pharmacologically allowable salt thereof and a polymer.
- the lower alkyl groups are straight or branched groups having 1 to 6 carbon atoms, and examples include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec -butyl group, a tert -butyl group, a pentyl group, a neopentyl group, and a hexyl group.
- substituent groups of the substituted lower alkyl groups examples include a hydroxyl group and an acetyl group.
- the pharmacologically allowable salts of compounds (I) include pharmacologically allowable acid addition salts, metal salts, ammonium salts, organic acid amine addition salts, and amino acid addition salts.
- Examples of pharmacologically allowable acid addition salts of compounds (I) include inorganic acid salts such as hydrochlorides, sulfates, phosphates; and organic acid salts such as acetates, maleates, fumarates, tartrates, and citrates.
- Examples of pharmacologically allowable metal salts include alkali metal salts such as lithium salts, sodium salts, and potassium salts; alkaline earth metal salts such as magnesium salts and calcium salts; aluminum salts; and zinc salts.
- Examples of pharmacologically allowable ammonium salts include salts of ammonium or tetramethyl ammonium.
- Examples of pharmacologically allowable organic amine addition salts include addition salts of morpholine or piperidine.
- Examples of pharmacologically allowable amino acid addition salts include addition salts of lysine, glycine, phenylalanine, glutamic acid, and aspartic acid.
- a compound (I) or a pharmacologically allowable salt thereof is contained at 1 to 50% by weight, and preferably, 3 to 10% by weight.
- the polymer to be used in the present invention is not particularly limited so long as it can disperse compounds (I) or pharmacologically allowable salts thereof, and accordingly, several natural polymers and synthetic polymers can be used.
- polymers include rubber compounds such as gum arabic; gelatin; polysaccharides such as agar; cellulose compounds or derivatives thereof such as crystalline cellulose, micro crystalline cellulose, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, carboxymethyl ethyl cellulose, ethyl cellulose, and cellulose acetate phthalate; polyvinyl derivatives such as polyvinyl alcohol, polyvinyl pyrrolidone, and polyvinyl acetal diethylaminoacetate; aminoalkyl methacrylate copolymers such as aminoalkyl methacrylate copolymer E
- enteric-coating polymers are preferred.
- enteric-coating polymers include methacrylate copolymer L (trade name: Eudragit L100 and Eudragit L100-55; Röhm Pharma Co., Ltd.), hydroxypropylmethyl cellulose phthalate (trade name: hydroxypropylmethyl cellulose phthalate HP-55; Shin-Etsu Chemical Co., Ltd.), hydroxypropylmethyl cellulose acetate succinate, and carboxymethylethyl cellulose.
- methacrylate copolymer L (trade name: Eudragit L100) is preferably used.
- Such a polymer is contained in the solid dispersion or the solid dispersion dosage form at 3 to 50% by weight, and preferably, 9 to 10% by weight.
- the blending ratio of a compound (I) to the polymer is 3:1 to 1:5 (by weight).
- the blending ratio is preferably 1:3
- the content of a compound (I) or a pharmacologically allowable salt thereof is 10 to 20% by weight
- the blending ratio is preferably 1:1.
- the solid dispersion of the present invention can be prepared by a co-grinding method, a solvent method, a melting method, a heat-melt-kneading method, or the like.
- a compound (I) or a pharmacologically allowable salt thereof is mixed with a polymer using a mixer or the like, and the mixture is ground using a grinder or the like.
- a compound (I) or a pharmacologically allowable salt thereof and a polymer are dissolved or dispersed in an organic solvent, and the organic solvent is then removed according to an ordinary method under reduced pressure or ordinary pressure.
- the organic solvent to be used in the solvent method is not particularly limited so long as it can dissolve a compound (I) or a pharmacologically allowable salt thereof and a polymer.
- organic solvents include aliphatic halogenated hydrocarbons, ketones, alcohols, ethers, aliphatic hydrocarbons, aromatic hydrocarbons, esters, organic acids, amides, and mixed solvents thereof.
- aliphatic halogenated hydrocarbons include methylene chloride, dichloroethane, and chloroform.
- ketones include acetone and methyl ethyl ketone.
- alcohols include methanol, ethanol, propanol, and butanol.
- ethers include diethyl ether, dibutyl ether, diisobutyl ether, dioxane, tetrahydrofuran, and ethylene glycol dimethyl ether.
- aliphatic hydrocarbons include n-hexane, cyclohexane, and n-heptane.
- aromatic hydrocarbons include benzene, toluene, and xylene.
- esters include ethyl acetate.
- organic acids include acetic acid and propionic acid.
- amides include dimethylformamide and dimethylacetamide.
- Aliphatic halogenated hydrocarbons, alcohols, and mixtures of aliphatic halogenated hydrocarbons and alcohols are preferably used, and an ethanol/methylene chloride (1/1) mixture is particularly preferably used.
- operating conditions such as the treatment temperature and time period are ordinarily at room temperature to 150°C and for several minutes to more than ten hours, though they are altered depending on the compound, the polymer, the solvent, or the like to be used.
- the solid dispersion is produced using, for example, a fluidized-bed granulator, an agitating granulator, a spray-dry granulator, or a vacuum-dry granulator, and specifically, is produced as follows.
- a compound (I) or a pharmacologically allowable salt thereof is dissolved in an organic solvent with a polymer to prepare a spray solution.
- a surfactant may be added to the spray solution.
- surfactants include sodium lauryl sulfate, polysolbate 80, and sucrose-fatty acid esters.
- sucrose-fatty acid esters having high HLB values such as a sucrose-fatty acid ester having an HLB value of 22 (Ryoto-Sugar Ester DK-SS; Mitsubishi Chemical Corporation) are preferably used.
- the surfactant concentration is preferably 0.1 to 5.0% by weight.
- the solid ingredient concentration based on the compound (I) or the pharmacologically allowable salt thereof and the polymer is 5 to 23% by weight/volume, preferably 11 to 15% by weight/volume, and more preferably 15% by weight/volume.
- the solid dispersion dosage form of the present invention can be obtained by spray-drying such a spray solution or spraying it onto an absorbent carrier, or by injecting it into water and isolating the resulting granules. Excipients ordinarily used in the pharmaceutical field can be used as absorbent carriers.
- excipients include saccharides such as lactose, sucrose, glucose, reducing maltose, mannitol, and sorbitol; starch or derivatives thereof such as corn starch, potato starch, dextrin, and pullulane; cellulose compounds such as crystalline cellulose and micro crystalline cellulose; amino acids such as arginine, asparagine, aspartic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, homoserine, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine; aminobutyric acid; aminocapronic acid; and glycylglycine.
- lactose products those having a mesh size of #200 are particularly preferred.
- a granulator for performing such spray-drying, a granulator may be used which is further equipped with a vacuum-drying unit or a microwave drying unit.
- a compound (I) or a pharmacologically allowable salt thereof is melted or dispersed in a polymer, and then quenched.
- the mixture is heated above the melting point or softening point of the compound (I), the pharmacologically allowable salt thereof, or the polymer.
- additives such as plasticizers or the aforementioned surfactants can be added.
- plasticizers include triethyl citrate, polyethylene glycol, and triacetin.
- the solid dispersion is produced using, for example, an agitating granulator with a heating unit.
- the compound (I) or the pharmacologically allowable salt thereof and the polymer are physically mixed beforehand.
- the aforementioned plasticizers, surfactants, or the like may be added as occasion demands.
- Operating conditions such as the treatment temperature and time period are ordinarily at room temperature to 150°C and for several minutes to more than ten hours, though these are altered depending on the compound, the polymer, concentrations or types of additives, or the like to be used.
- quenching is carried out to obtain the solid dispersion.
- the quenching temperature is -80°C to room temperature.
- a solid dispersion is obtained by a mixing process under heat and compression using an extruder having a heating unit, for example, a biaxial extruder.
- Operating conditions such as the treatment temperature, pressure, and time period are ordinarily at room temperature to 150°C, under 10 to 200 kg/cm 2 , and for several minutes to more than ten hours, though they are altered depending on the compound, the polymer, concentrations or types of additives, or the like to be used.
- a solid dispersion is produced using, for example, a biaxial extruder, and is specifically produced as follows.
- a compound (I) or a pharmacologically allowable salt thereof and a polymer, and optional additives as described above are physically mixed beforehand. This mixture is then fed at a powder feeding rate of 10 to 200 g/min. As to treatment conditions, the screw rotating speed is 50 to 300 r.p.m., the temperature is 20 to 200°C, and the pressure is 40 to 120 kg/cm 2 . Thus, a solid dispersion having a plastic characteristic can be obtained. Solid dispersion powder can be obtained by grinding the solid dispersion using a grinder.
- Solid dispersions of compounds (I) or pharmacologically allowable salts thereof obtained according to the co-grinding method, the solvent method, the melting method, the heat-melt-kneading method, or the like can be used as they are in the form of a powder or granular dosage form. Alternatively, they may be further transformed into solid dispersion dosage forms through a formulating process such as a mixing process, a granulating process, a tabletting process, an encapsulating process, and a coating process.
- the mixing process is, for example, a process for mixing such a solid dispersion and other compound using a mixer or the like.
- the granulating process is, for example, a process for granulating such a solid dispersion using a granulating mixer or the like.
- the tabletting process is, for example, a process for making such a solid dispersion into tablets using a tabletting machine or the like.
- the encapsulating process is, for example, a process for packing such a solid dispersion in capsules using an encapsulating machine or the like.
- the coating process is, for example, a process for coating such a solid dispersion with a coating agent using a coating machine or the like.
- Dosage forms obtained according to the above-described manner include parvule dosage forms, granular dosage forms, tablets, capsule dosage forms, or the like.
- an additive such as a coloring agent, a corrigent, an excipient, a disintegrator, a lubricant, and a surfactant can be added as occasion demands.
- coloring agents include yellow iron sesquioxide, iron sesquioxide, several food dyes, and copper sodium chlorophyllin.
- Examples of corrigents include sucrose, saccharin, aspartame, mannitol, dextran, a lemon flavor, menthol, and citric acid.
- excipients include the aforementioned excipients.
- disintegrators include hydroxypropyl cellulose, sodium croscarmellose, crospovidone, and sodium carboxymethyl starch.
- lubricants include magnesium stearate.
- surfactants include the aforementioned surfactants.
- magnesium stearate as a lubricant should preferably be mixed before the encapsulating or tabletting process in order to prevent powder adhesion onto the piston or punch.
- the solid dispersions of the present invention have greater absorbability than the crystal of Compound No. 1 and the dosage form of Comparative Example 1.
- Fig. 1 shows the results of the dissolution tests for the solid dispersions of Examples 1 to 3, the crystal of Compound No. 1, and the dosage form of Comparative Example 1.
- the results for the dosage form of Example 1 are represented by black dots
- those for the solid dispersion of Example 2 are represented by black squares
- those for the solid dispersion of Example 3 are represented by black triangles
- those for the crystal of Compound No. 1 are represented by white squares
- those for the dosage form of Comparative Example 1 are represented by white dots.
- Fig. 2 shows the results of measurement by a differential scanning calorimeter (DSC) for Compound No. 1.
- Fig. 3 shows the results of DSC measurement for a physically mixed composition according to the same recipe as the solid dispersion of Example 3.
- Fig. 4 shows the results of DSC measurement for the solid dispersion of Example 3.
- Fig. 5 shows the results of DSC measurement for the solid dispersion of Example 4.
- Fig. 6 shows the results of DSC measurement for the solid dispersion of Example 5.
- a solid dispersion containing 20% by weight of Compound No. 1 was obtained in a manner similar to that in Example 1 except that the quantity of Compound 1 was 200 g, that of methacrylate copolymer L was 200 g, and that of lactose was 600 g.
- the results of DSC measurement on Compound No. 1 alone are shown in Fig. 2, those on a physically mixed composition according to the same recipe as a solid dispersion containing 20% by weight of Compound No. 1 are shown in Fig. 3, and those on a solid dispersion containing 20% by weight of Compound No. 1 are shown in Fig. 4. Since the melting point peak of Compound No. 1, which appears in Figs. 2 and 3, disappears in Fig. 4, it is suggested that the solid dispersion according to the present invention became amorphous.
- a solid dispersion containing 3% by weight of Compound No. 1 was obtained in a manner similar to that in Example 1 except that a water-soluble polymer, polyvinyl pyrrolidone K30, was used instead of methacrylate copolymer L.
- Example 1 The solid dispersion obtained in Example 1 was packed in Size 0 of gelatin hard capsules at 333.3 mg to obtain solid dispersion dosage forms each containing 10 mg of Compound No. 1.
- Example 2 The solid dispersion obtained in Example 2 was packed in Size 2 of gelatin hard capsules at 150.0 mg to obtain solid dispersion dosage forms each containing 30 mg of Compound No. 1.
- Example 3 The solid dispersion obtained in Example 3 was packed in Size 0 of gelatin hard capsules at 333.3 mg to obtain solid dispersion dosage forms each containing 10 mg of Compound No. 1.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- The present invention relates to a solid dispersion and a solid dispersion dosage form of a xanthine derivative or a pharmacologically allowable salt thereof which exhibits an antagonistic activity relative to the adenosine A1 receptor, and which has a diuretic activity, a kidney-protecting activity, a bronchodilating activity, a cerebral function-improving activity, an anti-dementia activity, or the like.
- In general, drugs which are slightly soluble in water and have high crystallinity have low bioavailability since they have low solubility and low disolution rate in the gastrointestinal tract. Hitherto, in order to improve their absorbability, several methods for finely grinding drug crystals or for transforming them into amorphous substances have been examined.
- By fine-grinding, however, particle diameters become irregular between lots, or inter-particle force is enhanced to cause agglomeration.
- As a method for obtaining amorphous substances, grinding or forming a solid dispersion are considered. Drug crystals which can become amorphous by grinding are limited. Further, it has been known that solubility and absorbability of a slightly water-soluble compound are improved by dispersing it in a polymer to form a solid dispersion.
- As to xanthine derivatives or pharmacologically allowable salts thereof, which are slightly soluble, however, solid dispersions or solid dispersion dosage forms are not yet known.
- The present invention relates to a solid dispersion comprising a xanthine derivative or a pharmacologically allowable salt thereof and a polymer, the xanthine derivative [hereinafter referred to as compound (I)] being represented by the following formula (I).
- Furthermore, the present invention relates to a solid dispersion dosage form comprising a xanthine derivative of a compound (I) or a pharmacologically allowable salt thereof and a polymer.
- In the definition of the formula (I), the lower alkyl groups are straight or branched groups having 1 to 6 carbon atoms, and examples include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, a neopentyl group, and a hexyl group. As to substituent groups of the substituted lower alkyl groups, examples include a hydroxyl group and an acetyl group.
- The pharmacologically allowable salts of compounds (I) include pharmacologically allowable acid addition salts, metal salts, ammonium salts, organic acid amine addition salts, and amino acid addition salts.
- Examples of pharmacologically allowable acid addition salts of compounds (I) include inorganic acid salts such as hydrochlorides, sulfates, phosphates; and organic acid salts such as acetates, maleates, fumarates, tartrates, and citrates. Examples of pharmacologically allowable metal salts include alkali metal salts such as lithium salts, sodium salts, and potassium salts; alkaline earth metal salts such as magnesium salts and calcium salts; aluminum salts; and zinc salts. Examples of pharmacologically allowable ammonium salts include salts of ammonium or tetramethyl ammonium. Examples of pharmacologically allowable organic amine addition salts include addition salts of morpholine or piperidine. Examples of pharmacologically allowable amino acid addition salts include addition salts of lysine, glycine, phenylalanine, glutamic acid, and aspartic acid.
- Compounds (I) or pharmacologically allowable salts thereof can be produced according to the method described in Japanese Unexamined Patent Publication No. 3-173889.
-
- In the solid dispersion or the solid dispersion dosage form, a compound (I) or a pharmacologically allowable salt thereof is contained at 1 to 50% by weight, and preferably, 3 to 10% by weight.
- The polymer to be used in the present invention is not particularly limited so long as it can disperse compounds (I) or pharmacologically allowable salts thereof, and accordingly, several natural polymers and synthetic polymers can be used. Examples of polymers include rubber compounds such as gum arabic; gelatin; polysaccharides such as agar; cellulose compounds or derivatives thereof such as crystalline cellulose, micro crystalline cellulose, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, carboxymethyl ethyl cellulose, ethyl cellulose, and cellulose acetate phthalate; polyvinyl derivatives such as polyvinyl alcohol, polyvinyl pyrrolidone, and polyvinyl acetal diethylaminoacetate; aminoalkyl methacrylate copolymers such as aminoalkyl methacrylate copolymer E and aminoalkyl methacrylate copolymer RS; and methacrylate copolymers such as methacrylate copolymer L, methacrylate copolymer LD, and methacrylate copolymer S. Among these polymers, enteric-coating polymers are preferred. Examples of enteric-coating polymers include methacrylate copolymer L (trade name: Eudragit L100 and Eudragit L100-55; Röhm Pharma Co., Ltd.), hydroxypropylmethyl cellulose phthalate (trade name: hydroxypropylmethyl cellulose phthalate HP-55; Shin-Etsu Chemical Co., Ltd.), hydroxypropylmethyl cellulose acetate succinate, and carboxymethylethyl cellulose. Particularly, methacrylate copolymer L (trade name: Eudragit L100) is preferably used.
- Such a polymer is contained in the solid dispersion or the solid dispersion dosage form at 3 to 50% by weight, and preferably, 9 to 10% by weight.
- In the solid dispersion or the solid dispersion dosage form of the present invention, the blending ratio of a compound (I) to the polymer is 3:1 to 1:5 (by weight). In particular, when the content of a compound (I) or a pharmacologically allowable salt thereof is 3% by weight, the blending ratio is preferably 1:3, and when the content of a compound (I) or a pharmacologically allowable salt thereof is 10 to 20% by weight, the blending ratio is preferably 1:1.
- The solid dispersion of the present invention can be prepared by a co-grinding method, a solvent method, a melting method, a heat-melt-kneading method, or the like.
- In the co-grinding method, a compound (I) or a pharmacologically allowable salt thereof is mixed with a polymer using a mixer or the like, and the mixture is ground using a grinder or the like. In the solvent method, a compound (I) or a pharmacologically allowable salt thereof and a polymer are dissolved or dispersed in an organic solvent, and the organic solvent is then removed according to an ordinary method under reduced pressure or ordinary pressure.
- The organic solvent to be used in the solvent method is not particularly limited so long as it can dissolve a compound (I) or a pharmacologically allowable salt thereof and a polymer. Examples of such organic solvents include aliphatic halogenated hydrocarbons, ketones, alcohols, ethers, aliphatic hydrocarbons, aromatic hydrocarbons, esters, organic acids, amides, and mixed solvents thereof. Examples of aliphatic halogenated hydrocarbons include methylene chloride, dichloroethane, and chloroform. Examples of ketones include acetone and methyl ethyl ketone. Examples of alcohols include methanol, ethanol, propanol, and butanol. Examples of ethers include diethyl ether, dibutyl ether, diisobutyl ether, dioxane, tetrahydrofuran, and ethylene glycol dimethyl ether. Examples of aliphatic hydrocarbons include n-hexane, cyclohexane, and n-heptane. Examples of aromatic hydrocarbons include benzene, toluene, and xylene. Examples of esters include ethyl acetate. Examples of organic acids include acetic acid and propionic acid. Examples of amides include dimethylformamide and dimethylacetamide. Aliphatic halogenated hydrocarbons, alcohols, and mixtures of aliphatic halogenated hydrocarbons and alcohols are preferably used, and an ethanol/methylene chloride (1/1) mixture is particularly preferably used.
- As to removal of the organic solvent, operating conditions such as the treatment temperature and time period are ordinarily at room temperature to 150°C and for several minutes to more than ten hours, though they are altered depending on the compound, the polymer, the solvent, or the like to be used.
- According to the solvent method, the solid dispersion is produced using, for example, a fluidized-bed granulator, an agitating granulator, a spray-dry granulator, or a vacuum-dry granulator, and specifically, is produced as follows.
- A compound (I) or a pharmacologically allowable salt thereof is dissolved in an organic solvent with a polymer to prepare a spray solution. At this point, a surfactant may be added to the spray solution. Examples of surfactants include sodium lauryl sulfate, polysolbate 80, and sucrose-fatty acid esters. Although there exist several sucrose-fatty acid esters having different HLB values which vary depending on the carbon chain of the fatty acid or the ester concentration, sucrose-fatty acid esters having high HLB values such as a sucrose-fatty acid ester having an HLB value of 22 (Ryoto-Sugar Ester DK-SS; Mitsubishi Chemical Corporation) are preferably used. The surfactant concentration is preferably 0.1 to 5.0% by weight.
- In such a spray solution, the solid ingredient concentration based on the compound (I) or the pharmacologically allowable salt thereof and the polymer is 5 to 23% by weight/volume, preferably 11 to 15% by weight/volume, and more preferably 15% by weight/volume.
- The solid dispersion dosage form of the present invention can be obtained by spray-drying such a spray solution or spraying it onto an absorbent carrier, or by injecting it into water and isolating the resulting granules. Excipients ordinarily used in the pharmaceutical field can be used as absorbent carriers. Examples of excipients include saccharides such as lactose, sucrose, glucose, reducing maltose, mannitol, and sorbitol; starch or derivatives thereof such as corn starch, potato starch, dextrin, and pullulane; cellulose compounds such as crystalline cellulose and micro crystalline cellulose; amino acids such as arginine, asparagine, aspartic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, homoserine, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine; aminobutyric acid; aminocapronic acid; and glycylglycine. For example, among lactose products, those having a mesh size of #200 are particularly preferred.
- For performing such spray-drying, a granulator may be used which is further equipped with a vacuum-drying unit or a microwave drying unit.
- In the melting method, a compound (I) or a pharmacologically allowable salt thereof is melted or dispersed in a polymer, and then quenched. For melting or dispersing, for example, the mixture is heated above the melting point or softening point of the compound (I), the pharmacologically allowable salt thereof, or the polymer. In this case, additives such as plasticizers or the aforementioned surfactants can be added. Examples of plasticizers include triethyl citrate, polyethylene glycol, and triacetin.
- According to the melting method, the solid dispersion is produced using, for example, an agitating granulator with a heating unit. The compound (I) or the pharmacologically allowable salt thereof and the polymer are physically mixed beforehand. To this mixture, the aforementioned plasticizers, surfactants, or the like may be added as occasion demands. Operating conditions such as the treatment temperature and time period are ordinarily at room temperature to 150°C and for several minutes to more than ten hours, though these are altered depending on the compound, the polymer, concentrations or types of additives, or the like to be used. Subsequently, quenching is carried out to obtain the solid dispersion. The quenching temperature is -80°C to room temperature.
- In the heat-melt-kneading method, a solid dispersion is obtained by a mixing process under heat and compression using an extruder having a heating unit, for example, a biaxial extruder. Operating conditions such as the treatment temperature, pressure, and time period are ordinarily at room temperature to 150°C, under 10 to 200 kg/cm2, and for several minutes to more than ten hours, though they are altered depending on the compound, the polymer, concentrations or types of additives, or the like to be used.
- According to the heat-melt-kneading method, a solid dispersion is produced using, for example, a biaxial extruder, and is specifically produced as follows.
- A compound (I) or a pharmacologically allowable salt thereof and a polymer, and optional additives as described above are physically mixed beforehand. This mixture is then fed at a powder feeding rate of 10 to 200 g/min. As to treatment conditions, the screw rotating speed is 50 to 300 r.p.m., the temperature is 20 to 200°C, and the pressure is 40 to 120 kg/cm2. Thus, a solid dispersion having a plastic characteristic can be obtained. Solid dispersion powder can be obtained by grinding the solid dispersion using a grinder.
- Solid dispersions of compounds (I) or pharmacologically allowable salts thereof obtained according to the co-grinding method, the solvent method, the melting method, the heat-melt-kneading method, or the like can be used as they are in the form of a powder or granular dosage form. Alternatively, they may be further transformed into solid dispersion dosage forms through a formulating process such as a mixing process, a granulating process, a tabletting process, an encapsulating process, and a coating process.
- The mixing process is, for example, a process for mixing such a solid dispersion and other compound using a mixer or the like. The granulating process is, for example, a process for granulating such a solid dispersion using a granulating mixer or the like. The tabletting process is, for example, a process for making such a solid dispersion into tablets using a tabletting machine or the like. The encapsulating process is, for example, a process for packing such a solid dispersion in capsules using an encapsulating machine or the like. The coating process is, for example, a process for coating such a solid dispersion with a coating agent using a coating machine or the like.
- Dosage forms obtained according to the above-described manner include parvule dosage forms, granular dosage forms, tablets, capsule dosage forms, or the like. Further, an additive such as a coloring agent, a corrigent, an excipient, a disintegrator, a lubricant, and a surfactant can be added as occasion demands. Such an additive can be added in a manner suitable for each process. Examples of coloring agents include yellow iron sesquioxide, iron sesquioxide, several food dyes, and copper sodium chlorophyllin. Examples of corrigents include sucrose, saccharin, aspartame, mannitol, dextran, a lemon flavor, menthol, and citric acid. Examples of excipients include the aforementioned excipients. Examples of disintegrators include hydroxypropyl cellulose, sodium croscarmellose, crospovidone, and sodium carboxymethyl starch. Examples of lubricants include magnesium stearate. Examples of surfactants include the aforementioned surfactants.
- When an automatic encapsulating or tabletting machine is used, 0.5 to 2% by weight of magnesium stearate as a lubricant should preferably be mixed before the encapsulating or tabletting process in order to prevent powder adhesion onto the piston or punch.
- Advantages of the solid dispersion or the solid dispersion dosage form according to the present invention will be illustrated with experimental examples.
- One point six seven gram of each of the solid dispersions obtained in Examples 1 and 3, and 0.50 g of the solid dispersion obtained in Example 2 were each put in 900 ml of a solution containing 0.3% by weight of sodium lauryl sulfate in order to perform an dissolution test by a puddle method at 37°C and 100 r.p.m. The results are shown in Fig. 1. For comparison, similar dissolution tests were performed using 50 mg of Compound No. 1 crystals and tablets obtained in Comparative Example 1 instead of the solid dispersion. The results are shown in Fig. 1. As is revealed in Fig. 1, the solubility of the solid dispersions according to the present invention was significantly higher than those of the Compound No. 1 crystal and the dosage form obtained in Comparative Example 1.
- The solid dispersion dosage forms obtained in Examples 6, 7, and 8 were each orally administrated to a male beagle with 20 ml of water. For comparison, dosage forms each comprising 5 mg of Compound No. 1 crystals packed in a gelatin hard capsule and tablets of Comparative Example 1 were administrated to beagles in a similar manner. The dosage of each dosage form (the weight of Compound No. 1 per 1 kg body weight), and the number of dogs per group are shown in Table 2.
TABLE 2 Dosage (mg/kg) Number of Dogs (per group) Example 6 3 5 Example 7 3 4 Example 8 3 5 Crystal of Compound No. 1 6 2 Comparative Example 1 4 5 - Pharmacokinetic parameters in the results of this comparative absorbability test are shown in Table 3.
TABLE 3 The Area under the Plasma Concentration Curve (0 - 24, ng·h/ml) Administrated Formulation Intact Drug (in terms of 3 mg/kg) Example 6 404.3 ± 80.1 Example 7 156.2 ± 141.5 Example 8 110.3 ± 53.6 Crystal of Compound No. 1 69.9 ± 2.6 Comparative Example 1 77.3 ± 61.8 - As is revealed from the results of this comparative absorbability test, the solid dispersions of the present invention have greater absorbability than the crystal of Compound No. 1 and the dosage form of Comparative Example 1.
- Fig. 1 shows the results of the dissolution tests for the solid dispersions of Examples 1 to 3, the crystal of Compound No. 1, and the dosage form of Comparative Example 1. The results for the dosage form of Example 1 are represented by black dots, those for the solid dispersion of Example 2 are represented by black squares, those for the solid dispersion of Example 3 are represented by black triangles, those for the crystal of Compound No. 1 are represented by white squares, and those for the dosage form of Comparative Example 1 are represented by white dots.
- Fig. 2 shows the results of measurement by a differential scanning calorimeter (DSC) for Compound No. 1.
- Fig. 3 shows the results of DSC measurement for a physically mixed composition according to the same recipe as the solid dispersion of Example 3.
- Fig. 4 shows the results of DSC measurement for the solid dispersion of Example 3.
- Fig. 5 shows the results of DSC measurement for the solid dispersion of Example 4.
- Fig. 6 shows the results of DSC measurement for the solid dispersion of Example 5.
- Thirty grams of Compound No. 1 and 90 g of methacrylate copolymer L (Eudragit L100; Röhm Pharma Co., Ltd.) were dissolved in 700 g of an ethanol/methylene chloride (1/1 by weight) mixed solution, and the resultant was then sprayed on 880 g of lactose (#200 mesh) by a fluidized-bed granulating method to obtain a solid dispersion. Concerning the conditions for the fluidized-bed granulating at this time, the intake air temperature was 60°C, the solid ingredient concentration in the spray solution was 15% by weight/volume, and the spraying pressure was 2.0 kg/cm2. The powder characteristics of the solid dispersion containing 3% by weight of Compound No. 1 are shown in Table 4.
TABLE 4 Apparent Specific Volume Loose Specific Volume (ml/g) 2.32 Tapped Specific Volume (ml/g) 1.75 - A solid dispersion containing 20% by weight of Compound No. 1 was obtained in a manner similar to that in Example 1 except that the quantity of Compound 1 was 200 g, that of methacrylate copolymer L was 200 g, and that of lactose was 600 g. The results of DSC measurement on Compound No. 1 alone are shown in Fig. 2, those on a physically mixed composition according to the same recipe as a solid dispersion containing 20% by weight of Compound No. 1 are shown in Fig. 3, and those on a solid dispersion containing 20% by weight of Compound No. 1 are shown in Fig. 4. Since the melting point peak of Compound No. 1, which appears in Figs. 2 and 3, disappears in Fig. 4, it is suggested that the solid dispersion according to the present invention became amorphous.
- A solid dispersion containing 3% by weight of Compound No. 1 was obtained in a manner similar to that in Example 1 except that a water-soluble polymer, polyvinyl pyrrolidone K30, was used instead of methacrylate copolymer L.
- Using a biaxial extruder (manufactured by Kurimoto, Ltd.), 75 g of Compound No. 1 and 225 g of methacrylate copolymer L (Eudragit L100; Röhm Pharma Co., Ltd.) were heat-melt-kneaded to obtain a solid dispersion in which the concentration of Compound No. 1 was 25% by weight. The results of DSC measurement on this solid dispersion are shown in Fig. 5. Since the melting point peak of Compound No. 1 disappears, it is suggested that the solid dispersion became amorphous.
- Using a biaxial extruder (manufactured by Kurimoto, Ltd.), 150 g of Compound No. 1 and 150 g of methacrylate copolymer L (Eudragit L100; Röhm Pharma Co., Ltd.) were heat-melt-kneaded to obtain a solid dispersion in which the concentration of Compound No. 1 was 50% by weight. The results of DSC measurement on this solid dispersion are shown in Fig. 6. Since the melting point peak of Compound No. 1 disappears, it is suggested that the solid dispersion became amorphous.
- The solid dispersion obtained in Example 1 was packed in
Size 0 of gelatin hard capsules at 333.3 mg to obtain solid dispersion dosage forms each containing 10 mg of Compound No. 1. - The solid dispersion obtained in Example 2 was packed in Size 2 of gelatin hard capsules at 150.0 mg to obtain solid dispersion dosage forms each containing 30 mg of Compound No. 1.
- The solid dispersion obtained in Example 3 was packed in
Size 0 of gelatin hard capsules at 333.3 mg to obtain solid dispersion dosage forms each containing 10 mg of Compound No. 1. - Forty point zero grams of a finely ground product of Compound No. 1, 137.6 g of lactose, 59.0 g of corn starch, and 13.0 g of polyvinyl pyrrolidone were fluidized-bed-granulated using a binder solution comprising 7.8 g of polyvinyl alcohol dissolved in 31.2 g of distilled water. To this granulated composition, 2.6 g of magnesium stearate was admixed to produce tablets. At this time, each tablet contained 20.0 mg of the finely ground product of Compound No. 1, 68.8 mg of lactose, 29.5 mg of corn starch, 6.5 mg of polyvinyl pyrrolidone, 3.9 mg of polyvinyl alcohol, and 1.3 mg of magnesium stearate.
- According to the present invention, there is provided a solid dispersion or a solid dispersion dosage form of a slightly-soluble and crystalline drug, compound (I), wherein the solid dispersion or the solid dispersion dosage form has high solubility and absorbability, and also has powder characteristics suitable for production at an industrial scale.
Claims (6)
- A solid dispersion comprising a xanthine derivative represented by the following formula (I) or a pharmacologically allowable salt thereof and a polymer:
- A solid dispersion dosage form comprising a xanthine derivative represented by the following formula (I) or a pharmacologically allowable salt thereof and a polymer:
- The solid dispersion according to Claim 1, wherein said polymer is an enteric-coating polymer.
- The solid dispersion dosage form according to Claim 2, wherein said polymer is an enteric-coating polymer.
- The solid dispersion according to Claim 1, wherein said polymer is selected from methacrylate copolymer L, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, or carboxymethylethyl cellulose.
- The solid dispersion dosage form according to Claim 2, wherein said polymer is selected from methacrylate copolymer L, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, or carboxymethylethyl cellulose.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP19005895 | 1995-07-26 | ||
JP19005895 | 1995-07-26 | ||
JP190058/95 | 1995-07-26 | ||
PCT/JP1996/001555 WO1997004782A1 (en) | 1995-07-26 | 1996-06-07 | Solid dispersion or solid dispersion preparation of xanthine derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0784974A1 true EP0784974A1 (en) | 1997-07-23 |
EP0784974A4 EP0784974A4 (en) | 2000-09-27 |
EP0784974B1 EP0784974B1 (en) | 2003-05-21 |
Family
ID=16251650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96916342A Expired - Lifetime EP0784974B1 (en) | 1995-07-26 | 1996-06-07 | preparation of xanthine derivatives in a solid dispersion |
Country Status (9)
Country | Link |
---|---|
US (1) | US6254889B1 (en) |
EP (1) | EP0784974B1 (en) |
JP (1) | JP3938938B2 (en) |
AT (1) | ATE240734T1 (en) |
DE (1) | DE69628276T2 (en) |
DK (1) | DK0784974T3 (en) |
ES (1) | ES2199289T3 (en) |
PT (1) | PT784974E (en) |
WO (1) | WO1997004782A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060216351A1 (en) * | 2001-06-22 | 2006-09-28 | Pfizer Inc. | Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers |
US7235260B2 (en) * | 2000-03-16 | 2007-06-26 | Pfizer Inc | Pharmaceutical compositions of a sparingly soluble glycogen phosphorylase inhibitor |
CN100395245C (en) * | 2003-05-09 | 2008-06-18 | 协和发酵工业株式会社 | Microcrystal |
WO2008131502A2 (en) * | 2007-04-27 | 2008-11-06 | Katholieke Universiteit Leuven | Antiviral compounds of the adamantane type |
US8026286B2 (en) | 1999-12-23 | 2011-09-27 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
US8257741B2 (en) | 1997-08-11 | 2012-09-04 | Bend Research, Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
US8481081B2 (en) * | 1999-02-10 | 2013-07-09 | Bend Research, Inc. | Pharmaceutical solid dispersions |
US10463740B2 (en) | 2012-06-21 | 2019-11-05 | Mayne Pharma International Pty. Ltd. | Itraconazole compositions and dosage forms, and methods of using the same |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6350786B1 (en) * | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
JP5159012B2 (en) * | 1999-12-23 | 2013-03-06 | メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド | Improved pharmaceutical composition for poorly soluble drugs |
WO2002043704A1 (en) * | 2000-12-01 | 2002-06-06 | Kyowa Hakko Kogyo Co., Ltd. | Composition improved in solubility or oral absorbability |
WO2002062393A2 (en) * | 2001-02-02 | 2002-08-15 | Metagenics, Inc. | Coating for orally administered compositions |
JP4310605B2 (en) * | 2001-05-25 | 2009-08-12 | 大塚製薬株式会社 | Pharmaceutical composition |
JP2005523262A (en) | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming substances |
DE60329744D1 (en) * | 2002-02-22 | 2009-12-03 | Ajinomoto Kk | AMINO ACID POWDER AND METHOD FOR THE PRODUCTION THEREOF |
US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
BRPI0409699A (en) * | 2003-04-25 | 2006-04-18 | Novacardia Inc | methods of inducing the diuretic effect, inducing, maintaining or restoring the diuretic effect of a non-adenosine modifying diuretic, maintaining, restoring or improving renal function in a patient, inducing diuresis, preventing the onset of renal impairment in a patient with fluid or CHF overload, treating CHF patients and improving overall health outcomes, pharmaceutical composition and uses |
EP1932529A1 (en) | 2003-04-25 | 2008-06-18 | Novacardia, Inc. | Method of improved diuresis in individuals with impaired renal function |
US20060293312A1 (en) * | 2003-04-25 | 2006-12-28 | Howard Dittrich | Method of improved diuresis in individuals with impaired renal function |
BRPI0413277A (en) | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | pharmaceutical compositions of amorphous drug adsorbates and lipophilic microphase forming materials |
BRPI0509753A (en) * | 2004-04-16 | 2007-10-16 | Novacardia Inc | pharmaceutical composition and method of treating cardiovascular disease |
US20080312587A1 (en) * | 2005-06-10 | 2008-12-18 | Gruenethal Gmbh | System for the Oral Administration of Solids to Persons Suffering from Dementia |
WO2007069675A1 (en) | 2005-12-14 | 2007-06-21 | Kyowa Hakko Kogyo Co., Ltd. | Easily absorbed oral preparation containing xanthine derivative |
JP2007308480A (en) * | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | Solid preparation containing enteric solid dispersion |
CN101466383A (en) * | 2006-06-16 | 2009-06-24 | 美国诺华卡迪亚公司 | Prolonged improvement of renal function comprising infrequent administration of an AAIRA |
WO2008121882A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Improved methods of administration of adenosine a1 receptor antagonists |
WO2008121893A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
WO2008135855A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
US8309129B2 (en) | 2007-05-03 | 2012-11-13 | Bend Research, Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
EP2162120B1 (en) | 2007-06-04 | 2016-05-04 | Bend Research, Inc | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
US9545384B2 (en) | 2007-06-04 | 2017-01-17 | Bend Research, Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate |
HUE043897T2 (en) | 2007-09-25 | 2019-09-30 | Solubest Ltd | Compositions comprising lipophilic active compounds and method for their preparation |
US9724362B2 (en) | 2007-12-06 | 2017-08-08 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
EP2240162A4 (en) | 2007-12-06 | 2013-10-09 | Bend Res Inc | Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer |
US20110021567A1 (en) * | 2008-03-11 | 2011-01-27 | Dr. Reddy's Laboratories Ltd. | Preparation of lenalidomide |
TWI615157B (en) * | 2013-02-06 | 2018-02-21 | 大塚製藥股份有限公司 | Solid dispersion comprising amorphous cilostazol |
EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
AR106018A1 (en) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS |
WO2018005552A1 (en) | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
WO2018160889A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
TWI780270B (en) | 2017-11-28 | 2022-10-11 | 靜岡縣公立大學法人 | Solid dispersion |
US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
JP7504088B2 (en) | 2018-10-16 | 2024-06-21 | ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド | Carbon monoxide prodrugs for the treatment of medical disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0415456A2 (en) * | 1989-09-01 | 1991-03-06 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3976071A (en) * | 1974-01-07 | 1976-08-24 | Dynatech Corporation | Methods of improving control of release rates and products useful in same |
US5286489A (en) * | 1985-08-26 | 1994-02-15 | The Procter & Gamble Company | Taste masking compositions |
GB2201594B (en) * | 1986-06-24 | 1991-02-13 | Istvan Racz | Production of acid binding pharmaceutical preparations |
JP2521461B2 (en) * | 1987-03-10 | 1996-08-07 | エスエス製薬株式会社 | Persistent tablets |
ES2077023T3 (en) * | 1989-03-10 | 1995-11-16 | Yamanouchi Pharma Co Ltd | COATING MATERIAL THAT CONTROLS THE RELEASE OF A MEDICINAL PRODUCT FOR FORMULATIONS OF PROLONGED ACTIVITY. |
US5290782A (en) | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
WO1992018106A1 (en) * | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Method of manufacturing solid dispersion |
-
1996
- 1996-06-07 DE DE69628276T patent/DE69628276T2/en not_active Expired - Fee Related
- 1996-06-07 EP EP96916342A patent/EP0784974B1/en not_active Expired - Lifetime
- 1996-06-07 WO PCT/JP1996/001555 patent/WO1997004782A1/en active IP Right Grant
- 1996-06-07 US US08/809,651 patent/US6254889B1/en not_active Expired - Fee Related
- 1996-06-07 PT PT96916342T patent/PT784974E/en unknown
- 1996-06-07 AT AT96916342T patent/ATE240734T1/en not_active IP Right Cessation
- 1996-06-07 ES ES96916342T patent/ES2199289T3/en not_active Expired - Lifetime
- 1996-06-07 DK DK96916342T patent/DK0784974T3/en active
- 1996-06-07 JP JP50744297A patent/JP3938938B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0415456A2 (en) * | 1989-09-01 | 1991-03-06 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine compounds |
Non-Patent Citations (4)
Title |
---|
EL-BANNA H M ET AL: "THE APPLICATION OF SOLID DISPERSION TECHNIQUE IN THE PREPARATION OF THERAPEUTIC TABLETS. PART 1: PARACETAMOL, AMYLOBARBITONE, AND CAFFEINE TABLETS" PHARMAZIE,DD,VEB VERLAG VOLK UND GESUNDHEIT. BERLIN, vol. 32, no. 8/09, 1977, pages 511-515, XP002028983 ISSN: 0031-7144 * |
See also references of WO9704782A1 * |
YUASA H ET AL: "APPLICATION OF THE SOLID DISPERSION METHOD TO THE CONTROLLED RELEASE OF MEDICINE VI. RELEASE MECHANISM OF A SLIGHTLY WATER SOLUBLE MEDICINE AND INTERACTION BETWEEN FLURBIPROFEN AND HYDROXYPROPYL CELLULOSE IN SOLID DISPERSION" CHEMICAL AND PHARMACEUTICAL BULLETIN,JP,PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, vol. 42, no. 2, 1 February 1994 (1994-02-01), pages 354-358, XP000441941 ISSN: 0009-2363 * |
ZINGONE G ET AL: "Characterization and dissolution study of solid dispersions of theophylline and indomethacin with PVP/VA copolymers" STP PHARMA SCIENCES,FR,PARIS, vol. 2, no. 2, 1992, pages 186-192-192, XP002111752 ISSN: 1157-1489 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8257741B2 (en) | 1997-08-11 | 2012-09-04 | Bend Research, Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
US8431159B2 (en) | 1997-08-11 | 2013-04-30 | Bend Research, Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
US8367118B2 (en) | 1997-08-11 | 2013-02-05 | Bend Research, Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
US8337899B2 (en) | 1997-08-11 | 2012-12-25 | Bend Research, Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
US8263128B2 (en) | 1997-08-11 | 2012-09-11 | Bend Research, Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
US8481081B2 (en) * | 1999-02-10 | 2013-07-09 | Bend Research, Inc. | Pharmaceutical solid dispersions |
US8501231B2 (en) | 1999-12-23 | 2013-08-06 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
US8026286B2 (en) | 1999-12-23 | 2011-09-27 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
US8796341B2 (en) | 1999-12-23 | 2014-08-05 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
US8980321B2 (en) | 1999-12-23 | 2015-03-17 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
US9457095B2 (en) | 1999-12-23 | 2016-10-04 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
US7235260B2 (en) * | 2000-03-16 | 2007-06-26 | Pfizer Inc | Pharmaceutical compositions of a sparingly soluble glycogen phosphorylase inhibitor |
US20060216351A1 (en) * | 2001-06-22 | 2006-09-28 | Pfizer Inc. | Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers |
US9468604B2 (en) | 2001-06-22 | 2016-10-18 | Bend Research, Inc. | Pharmaceutical compositions of dispersions of drug and neutral polymers |
CN100395245C (en) * | 2003-05-09 | 2008-06-18 | 协和发酵工业株式会社 | Microcrystal |
WO2008131502A3 (en) * | 2007-04-27 | 2009-03-05 | Univ Leuven Kath | Antiviral compounds of the adamantane type |
WO2008131502A2 (en) * | 2007-04-27 | 2008-11-06 | Katholieke Universiteit Leuven | Antiviral compounds of the adamantane type |
US10463740B2 (en) | 2012-06-21 | 2019-11-05 | Mayne Pharma International Pty. Ltd. | Itraconazole compositions and dosage forms, and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
EP0784974A4 (en) | 2000-09-27 |
WO1997004782A1 (en) | 1997-02-13 |
PT784974E (en) | 2003-09-30 |
US6254889B1 (en) | 2001-07-03 |
DK0784974T3 (en) | 2003-09-01 |
DE69628276T2 (en) | 2004-04-08 |
DE69628276D1 (en) | 2003-06-26 |
EP0784974B1 (en) | 2003-05-21 |
ATE240734T1 (en) | 2003-06-15 |
JP3938938B2 (en) | 2007-06-27 |
ES2199289T3 (en) | 2004-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6254889B1 (en) | Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer | |
JP4334869B2 (en) | Compositions with improved solubility or oral absorption | |
AU623177B2 (en) | Granular pharmaceutical formulations | |
EP1291014B1 (en) | A process for producing a pharmaceutical solid preparation containing a poorly soluble drug | |
KR100660072B1 (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
JPH0751504B2 (en) | Vitamin granules for direct compression, production method and tablets | |
NZ245483A (en) | Process for preparing a solid dispersion of romglizone | |
JP2538134B2 (en) | Sustained release preparation and method for producing the same | |
AU2011244020A1 (en) | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same | |
AU778764B2 (en) | Quinolinone derivative pharmaceutical composition and production method therefor | |
CN109718215A (en) | A kind of Ezetimibe piece | |
ZA200207737B (en) | Granulated particles with masked taste. | |
JPH031288B2 (en) | ||
CA2201096C (en) | Solid dispersion and solid dispersion dosage form of xanthine derivative | |
JPH0328404B2 (en) | ||
EP0398033B1 (en) | Oral preparation | |
JP6072705B2 (en) | Solid dispersion formulation | |
EP0489181B1 (en) | Solid preparation | |
CA2118133C (en) | Aminoguanidine spray drying process | |
KR100981751B1 (en) | Granules containing pranlukast and processes for the preparation thereof | |
JP2813792B2 (en) | Preparation for oral administration of irsogladine maleate and its production method | |
EP1961422A1 (en) | Easily absorbed oral preparation containing xanthine derivative | |
JPH10298074A (en) | Composition containing vitamins | |
JPH08169847A (en) | Solid preparation | |
KR100759607B1 (en) | Cefuroxime axetil granule and process for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970425 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20000814 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20001115 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/52 A, 7A 61K 9/10 B |
|
RTI1 | Title (correction) |
Free format text: PREPARATION OF XANTHINE DERIVATIVES IN A SOLID DISPERSION |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/52 A, 7A 61K 9/10 B |
|
RTI1 | Title (correction) |
Free format text: PREPARATION OF XANTHINE DERIVATIVES IN A SOLID DISPERSION |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HAYAKAWA, EIJI Inventor name: ISHIKAWA, YASUHIRO Inventor name: UENO, YASUHIKO Inventor name: MASADA, TOMOAKI Inventor name: KIGOSHI, MAKOTO |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HAYAKAWA, EIJI Inventor name: ISHIKAWA, YASUHIRO Inventor name: UENO, YASUHIKO Inventor name: MASADA, TOMOAKI Inventor name: KIGOSHI, MAKOTO |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69628276 Country of ref document: DE Date of ref document: 20030626 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20030402912 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENTANWAELTE |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20030806 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2199289 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
ET | Fr: translation filed | ||
26N | No opposition filed |
Effective date: 20040224 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: KYOWA HAKKO KIRIN CO., LTD. Free format text: KYOWA HAKKO KOGYO CO., LTD.#6-1, OHTEMACHI 1-CHOME#CHIYODA-KU, TOKYO 100 (JP) -TRANSFER TO- KYOWA HAKKO KIRIN CO., LTD.#1-6-1, OHTEMACHI CHIYODA-KU#TOKYO 100-8185 (JP) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20090615 Year of fee payment: 14 Ref country code: MC Payment date: 20090619 Year of fee payment: 14 Ref country code: IE Payment date: 20090624 Year of fee payment: 14 Ref country code: DK Payment date: 20090615 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20090605 Year of fee payment: 14 Ref country code: PT Payment date: 20090605 Year of fee payment: 14 Ref country code: IT Payment date: 20090618 Year of fee payment: 14 Ref country code: FI Payment date: 20090616 Year of fee payment: 14 Ref country code: AT Payment date: 20090615 Year of fee payment: 14 |
|
NLT1 | Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1 |
Owner name: KYOWA HAKKO KIRIN CO., LTD. |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20090525 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20090710 Year of fee payment: 14 Ref country code: CH Payment date: 20090615 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20090720 Year of fee payment: 14 Ref country code: GR Payment date: 20090527 Year of fee payment: 14 Ref country code: GB Payment date: 20090603 Year of fee payment: 14 Ref country code: DE Payment date: 20090604 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20101207 |
|
BERE | Be: lapsed |
Owner name: KYOWA HAKKO KIRIN CO. LTD Effective date: 20100630 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20110101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100630 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100607 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL Ref country code: DK Ref legal event code: EBP |
|
EUG | Se: european patent has lapsed | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20100607 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20101207 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20110228 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100607 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100630 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100607 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100630 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100607 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100630 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100630 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110104 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20110718 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110706 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100607 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100608 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100607 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100608 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20090611 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20030402912 Country of ref document: GR Effective date: 20110104 |